Unlike in luminal breast cancer, Ki-67 has been reported by some to have no significant association with survival in HER2-positive and triple-negative tumors [68,70,71], although some authors have suggested that the lack of an observed association might be more due to use of lower cutoffs (such as 15%) that are more appropriate for luminal tumors [70]. This evidence concerns the gene ERBB2 and breast carcinoma.